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osting by EAbstract A new simple isocratic chiral liquid chromatographic method was developed for the
enantiomeric purity of Ramelteon [(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)
ethyl]-propionamide], a melatonin agonist in bulk drugs. The chromatographic separation was
achieved on Chiralpak AD-H, 250 mm · 4.6 mm, 5 lm column using a mobile phase system con-
sisting of n-hexane, ethanol and methanesulfonic acid in the ratio of 900:100:0.1 (v/v/v). The mobile
phase was pumped on the column at the ﬂow rate of 1 mL min1. Addition of methane sulfonic acid
in the mobile phase enhanced chromatographic efﬁciency and resolution between the enantiomers.
The resolution between the enantiomers was found to be more than four. The developed method
was subsequently validated and proved to be accurate and precise. The experimentally established
limit of detection and quantiﬁcation of (R)-enantiomer were found to be 25.5 and 77.2 ng ml1,
respectively, for 20 ll injection volumes. The percentage recovery of (R)-enantiomer was ranged
from 98.5 to 101.9 in bulk drug samples of Ramelteon. The stability of Ramelteon sample in ana-
lytical solution was checked for about 48 h at room temperature and was found to be stable for
about 48 h. The proposed method was found to be suitable and accurate for the quantitative deter-
mination of (R)-enantiomer in drug substance.
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lsevier1. Introduction
The biological activity of chiral substances often depends upon
their stereochemistry. A large percentage of commercial and
investigational pharmaceutical compounds are enantiomers,
and many of them show signiﬁcant enantioselective differences
in their pharmacokinetics and pharmacodynamics (Stinson,
2000, 2001; Thayer, 2008). Analysis of the enantiomeric purity
of chiral drug candidates has become very important particularly
in the pharmaceutical and biological ﬁelds, because few enantio-
mers of racemic drugs have relatively different pharmacokinetic
104 S.D. Patil et al.properties and diverse pharmacological or toxicological effects
(FDA, 1992; Ariens, 1984, 1986, 1987).
Enantiomeric separations have acquired importance in all
stages of drug development and commercialization process.
Therefore, the development of new methods for efﬁcient chiral
separations mainly based on HPLC (Nikolic et al., 2009;
Kubota et al., 2010; Kasawar and Farooqui, 2009; Meng
et al., 2010), capillary electrophoresis (CE) (Van Eeckhaut
and Michotte, 2006; Halabi et al., 2004) or gas chromatogra-
phy (GC) (Schurig, 2002; Ramos Mda et al., 2003) is more
than necessary. The chromatographic separation of enantio-
mers using high-performance liquid chromatography (HPLC)
with chiral stationary phases (CSPs) is one of the most useful
and popular techniques for enantiopurity analysis in pharma-
ceutical preparations and biological ﬂuids (Toribio et al., 2006;
Simplicio et al., 2006; Sellers et al., 2006).
Insomnia is a common sleep disorder with signiﬁcant
potential for deleterious effects on activity of daily living, pro-
ductivity and overall quality of life. Ramelteon, a highly selec-
tive agonist for melatonin subtypes 1 and 2 receptors, is a
hypnotic agent approved by the US Food and Drug Adminis-
tration (FDA) for the treatment of insomnia characterized by
difﬁculty falling asleep (Borja and Daniel, 2006).
Rameleteon, (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-
b]furan-8-yl)ethyl] propionamide (Fig. 1) structure is
composed of a substituted tetrahydroindenofuran derivative
containing a propionamide moiety with one chiral center,
and the compound is produced as the (S) enantiomer (Yamano
et al., 2006).
A thorough literature survey revealed that none of the most
recognized pharmacopoeias or journals include this drug for
the determination of chiral purity. The chiral purity of drug
is very important since only S-isomer of it is active and
R-isomer is inactive. So it is felt essential to develop a liquid
chromatographic procedure which will serve as a reliable,
accurate, sensitive and stability indicating normal phase
HPLC method for the determination of chiral purity of
Ramelteon.
2. Experimental
2.1. Chemicals
Ramelteon and (R)-enantiomer were kindly supplied by
School of chemical sciences, S.R.T.M. University Nanded, In-
dia and the chemical structure is shown in Fig. 1. HPLC grade
n-hexane and ethanol were purchased from Merck Ltd., Ger-
many. Laboratory reagent grade diethyl amine, triﬂuoroacetic
acid and methanesulfonic acid were purchased from Merck
Ltd., Germany.O
NH
CH3
O
S
Figure 1 Molecular structure of (S)-Ramelteon.2.2. Equipment
A Waters 2695 separation module (USA) equipped with an
auto injector was utilized for method development and valida-
tion. Empower software was used for data acquisition and sys-
tem suitability calculations.
2.3. Sample preparation
A solution containing racemic mixture of Ramelteon
(0.1 mg mL1) and sample solution of Ramelteon (1 mg mL1)
was prepared in n-hexane and ethanol in the ratio of 60:40 (v/v).
2.4. Chromatographic conditions
The chromatographic conditions were optimized using an
amylose-based chiral stationary phase Chiralpak AD-H
250 mm · 4.6 mm, 5 lm (Daicel), with safeguarded column
of 1 cm long. The mobile phase consisting of n-hexane, ethanol
and methanesulfonic acid in the ratio of 900:100:0.1 (v/v/v)
was pumped through the column at the ﬂow rate of
1.0 mL min1. The column compartment was maintained at
25 C and the detection was carried out at a wavelength of
220 nm. The injection volume was 20 ll. Amylose-based chiral
stationary phase Chiralpak AS-H (ChromTech), Cellulose
based chiral stationary phase Chiralcel OD-H (Diacel) and pir-
kle based chiral stationary phase Whelk-O-1 (Merck) were also
employed during method development.2.5. Validation of the method
2.5.1. Speciﬁcity
The speciﬁcity of the developed LC method was determined in
the presence of its related impurities and degradation products.
Forced degradation studies were also performed on Ramelteon
bulk drug sample to provide an indication of the stability indi-
cating property and speciﬁcity of the proposed method. The
stress conditions employed for degradation study include light
(1.2 million lux h/m2/22 h), heat (105 C/24 h), humidity
(40 C/75% RH/7 days), acid hydrolysis (0.1 N ethanolic
HCl/5 ml/3 h reﬂux), base hydrolysis (0.1 N ethanolic NaOH/
5 ml/3 h reﬂux), and peroxide degradation (3% w/v H2O2/
5 ml/3 h reﬂux). About 5–15% degradation was observed in
forced degradation studies and (R) enantiomer observed was
about 0.3% in both stressed and unstressed samples. The typi-
cal chromatograms of control sample and stressed samples
were represented in Fig. 2. Peak purity of stressed sample of
S-Ramelteon was checked by using photo diode array detector.
Purity angle was found less than purity threshold in all stress
samples and no interference was found from the blank which
demonstrate the analyte peak homogeneity.
2.5.2. Method reproducibility
Method reproducibility was determined by measuring repeat-
ability and intermediate precision (between-day precision) of
retention times and peak areas for each enantiomer. In order
to determine the repeatability of the method, replicate injec-
tions (n= 6) of a 1.0 mg/ml solution containing Ramelteon
and (R)-enantiomer was carried out. The intermediate
precision was also evaluated over 3 days by performing six
successive injections each day.
Figure 2 Typical HPLC chromatograms of pure and stressed samples. (A) Untreated sample, (B) sample stressed under heat, (C) sample
stressed under UV, (D) sample stressed under humidity, (E) sample treated with acid, (F) sample treated with base, and (G) sample treated
with peroxide. (Column: Chiralpak AD-H 250 mm · 4.6 mm, 5 lm, mobile phase: n-hexane:ethanol:methanesulfonic acid (900:100:0.1,
v/v/v), ﬂow rate: 1 ml/min, UV detection: 220 nm).
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Figure 2 (continued)
106 S.D. Patil et al.2.5.3. Linearity of (R)-enantiomer
The linearity of detector response was assessed by preparing
calibration curve of sample solutions (R-enantiomer) of 14
concentration levels covering from 20 ng mL1 to
2400 ng mL1 in n-hexane and ethanol in the ratio of 60:40
(v/v). Regression curve was obtained by plotting peak area
versus respective concentration, using the least squares meth-
od. The slope and intercept of the calibration curve was
calculated.2.5.4. Limit of detection and limit of quantiﬁcation of
(R)-enantiomer
The limit of detection is deﬁned as the lowest concentration of
analyte that can be clearly detected above the baseline signal,
while the limit of quantiﬁcation is deﬁned as the lowest concen-
tration of analyte that can be quantiﬁed with suitable precision
and accuracy. The linearity performed above is used for the
determination of limit of quantiﬁcation and detection. Resid-
ual standard deviation (r) method was applied to predict the
Table 2 Validation results of the developed chiral LC
method.
Validation parameter Results
Repeatability (n = 6, %RSD)
Retention time (S-enantiomer) 0.2
Retention time (R-enantiomer) 0.1
Peak area (S-enantiomer) 0.3
Peak area (R-enantiomer) 0.7
Intermediate precision (n = 18, %RSD)
Retention time (S-enantiomer) 0.3
Retention time (R-enantiomer) 0.2
Peak area (S-enantiomer) 0.4
Peak area (R-enantiomer) 0.8
LOD–LOQ (R-enantiomer)
Limit of detection (ng/ml) 25.5
Limit of quantiﬁcation (ng/ml) 77.2
Precision at LOQ (%RSD) 3.3
Linearity (R-enantiomer)
Calibration range (ng mL1) 80–2400
Calibration points 12
Correlation coeﬃcient 0.9997
Table 1 System-suitability report.
Compound (n= 3) Rt Rs N T
Ramelteon 10.2 – 6717 1.51
R() enantiomer 14.4 7.2 7544 1.51
n= 3 determinations. Rt: retention time, Rs: USP resolution, N:
number of theoretical plates (USP tangent method), T: USP tailing
factor.
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the precision was established at these predicted levels. The re-
sults are tabulated in Table 2
LOQ ¼ 10r=S ðaÞ
LOD ¼ 3:3r=S ðbÞ
where r= residual standard deviation of response; S= slope
of the calibration curve
2.5.5. Quantiﬁcation of (R)-enantiomer in bulk sample
Standard addition and recovery experiments were conducted
to determine the accuracy of the present method for the quan-
tiﬁcation of (R)-enantiomer in bulk drug samples. The study
was carried out in triplicate at 0.1%, 0.2% and 0.24% of the
target analyte concentration.
2.5.6. Robustness
Robustness of the method was performed by deliberately
changing the chromatographic conditions. The ﬂow rate of
the mobile phase was changed from 1.0 to 0.9 mL min1 and
1.1 mL min1. The ethanol strength of mobile phase was var-
ied by ±2% while column temperature was varied by ±5 C.
The solution of racemic mixture was injected in each varied
conditions and the resolution between the isomers was
checked. In all deliberately varied conditions, the resolution
between the isomers was found to be well within the accep-
tance limit of 2% indicating the method robustness.
2.5.7. Solution stability and mobile phase stability
Stability of Ramelteon in analytical solution at analyte concen-
tration was studied by keeping the solution in tightly capped
volumetric ﬂask at room temperature on a laboratory bench
for 2 days. Content of (R)-enantiomer was checked for 6 h
interval up to the study period. Mobile phase stability was car-
ried out by evaluating the content of (R)-enantiomer in
Ramelteon sample solutions prepared freshly at 6 h interval
for 2 days. Same mobile phase was used during the study
period.
3. Results and discussion
3.1. Optimization of chromatographic conditions
The aim of this work is to separate the enantiomers for the
accurate quantiﬁcation of (R)-enantiomer. Racemic mixture
solution of 10 mg mL1 prepared in n-hexane and ethanol in
the ratio of 60:40 (v/v) was used in the method development.
To develop a rugged and suitable LC method for the separa-
tion of Ramelteon enantiomers, different mobile phases and
stationary phases were employed. To achieve the chromato-
graphic separation, various chiral columns like Chiralcel
ODH, Chirapak AS-H, Chiralpak AD-H (Diacel) and
Whelk-O-1 (Merck) were used. Various experiments were con-
ducted, to select the best stationary and mobile phases that
would give optimum resolution and selectivity for the enantio-
mers. Poor separation was found on Chiralcel OD-H, Whelk-
O-1 and Chiralpak AS-H columns using different possible mo-
bile phases. There is an indication of separation on Chiralpak
AD-H column using a mobile phase consisting of n-hexane,
ethanol, and diethylamine in the ratio of 800:200:1 (v/v/v) as
well as n-hexane, ethanol, triﬂuoroacetic acid in the ratio of800:200:1 (v/v/v) but the peak shapes were found to be broad.
Introduction of methanesulfonic acid in the mobile phase im-
proved the chromatographic efﬁciency and resolution between
the enantiomers. Very good separation was achieved on Chir-
alpak AD-H column (resolution between enantiomers was
found greater than seven) using the mobile phase system n-hex-
ane, ethanol, methanesulfonic acid in the ratio of 900:100:0.1
(v/v/v) (Fig 3). Reversal of the elution order of the enantiomers
on changing from ethanol to 1-propanol was observed on
Chiralpak AD-H column. The chiral discrimination of enanti-
omers occurs when they bind with the stationary phase form-
ing transient diastereomeric complexes. The most important
interactions between the analyte and the chiral stationary
phase (CPS) are hydrogen bonding, dipole–dipole interactions,
and p–p interactions, together with the rigid structure (cellu-
lose-based CSP) or helical structure (amylose-based CSP) of
the chiral polymer bound to the support. The enantioselectiv-
ity changes suggest that the ethanol affects the steric environ-
ment of the chiral cavities or channels of the stationary phase.
Ramelteon has only one chiral center and an amylose-based
chiral stationary phase has ﬁve chiral centers per unit. It is pre-
sumed that it could be due to high probability of interaction,
better resolution was found on Chiralpak AD-H column.
Due to the better chromatographic results obtained on the
Chiralpak AD-H column, the method validation was carried
out on the same column. In the optimized method, the typical
retention times of Ramelteon and (R)-enantiomer were about
10 and 14.4 min, respectively. The enantiomeric separation of
Figure 3 Enantiomeric resolution of Ramelteon on Chiralpack AD-H column. (Column: Chiralpak AD-H 250 mm · 4.6 mm, 5 lm,
mobile phase: n-hexane:ethanol:methanesulfonic acid (900:100:0.1, v/v/v), ﬂow rate: 1 ml/min, UV detection: 220 nm).
Table 3 Recovery results of (R)-enantiomer in bulk drugs.
Amount
added (lg)
Amount
recovered (lg)
Recovery (%) RSD (%) n= 3
51.3 51.7 100.8 1.2
102.5 102.8 100.3 1.4
123.0 122.5 99.6 1.6
RSD: relative standard deviation.
Table 4 Robustness of the chiral LC method.
Parameter USP resolution between
Ramelteon and (R)-enantiomer
Flow rate (ml/min)
0.9 7.6
1.0 7.2
1.1 6.9
Column temperature (C)
20 7.5
25 7.2
30 7.0
Ethanol percentage in mobile phase
8 7.4
10 7.2
12 7.1
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The system suitability test results of the chiral LC method on
Chiralpak AD are presented in Table 1.
3.2. Validation results of the method
In the repeatability study, the percentage relative standard
deviation (%RSD) was found less than 0.5 for the retention
times of both the enantiomers, 0.7 for (R)-enantiomer peak
area and 0.3 for (S)-enantiomer peak area. In the intermediate
precision study, results show that %RSD values were in thesame order of magnitude than those obtained for repeatability.
The limit of detection (LOD) and limit of quantiﬁcation (LOQ)
concentrations were estimated to be 25.5 and 77.2 ng mL1 for
(R)-enantiomer. Good linearity was observed for (R)-enantio-
mer over the concentration range of 80–2400 ng mL1, with
the linear regression equation y= 31870.908x+ 326.919 (cor-
relation coefﬁcient R= 0.99968). The results are tabulated in
Table 2. The standard addition and recovery experiments were
conducted for (R)-enantiomer in bulk samples in triplicate at
0.1%, 0.2% and 0.24% of analyte concentration and percent-
age recovery was ranged from 98.5 to 101.9 (Table 3).
The chromatographic resolution between Ramelteon and
(R)-enantiomer peaks was used to evaluate the method robust-
ness under modiﬁed conditions. The resolution between
Ramelteon and (R)-enantiomer was greater than 6.0, under
all conditions tested (Table 4), demonstrating sufﬁcient robust-
ness. No signiﬁcant change in the (R)-enantiomer content was
observed in Ramelteon sample during solution stability and
mobile phase stability experiments. Hence, Ramelteon sample
solution and mobile phase was found stable for about 48 h.
4. Conclusion
A simple, rapid and accurate normal phase chiral LC method
was described for the enantiomeric separation of Ramelteon.
The method was completely validated showing satisfactory
data for all the method validation parameters tested. The
developed method is stability indicating and can be used for
the quantitative determination of chiral impurity ((R)-enantio-
mer) in bulk materials.Acknowledgments
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